An FDA committee unanimously recommended today that GlaxoSmithKline PLC's drug Advair should remain on the market to treat asthma in adults.
Copyright PHILY - Philly.com
An FDA committee unanimously recommended today that GlaxoSmithKline PLC's drug Advair should remain on the market to treat asthma in adults.